First patient dosed in Phase 3 iclaprim ABSSSI trial
2 March 2016 | By Victoria White
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections...
List view / Grid view
News
MAA submitted for haemophilia A treatment, Adynovi
2 March 2016 | By Victoria White
Adynovi is an extended circulating half-life recombinant Factor VIII treatment, for paediatric, adolescent and adult patients with haemophilia A...
Amgen submits sBLA for Blincyto to the FDA
2 March 2016 | By Victoria White
The sBLA includes new data supporting the treatment of paediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)...
Phase II trial of sulfatinib in thyroid cancer starts
2 March 2016 | By Victoria White, Digital Content Producer
The trial will evaluate sulfatinib in locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer....
Breast cancer treatment pipeline has over 1,000 drugs in development
1 March 2016 | By Victoria White
The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape, says GBI Research...
MAA submitted for tivozanib for the treatment of RCC
1 March 2016 | By Victoria White
Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)...
FDA approves Gazyva to treat follicular lymphoma
1 March 2016 | By Victoria White
The FDA has approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma...
Quotient Clinical showcases Enabled-First-in-Human® programs at ASCPT 2016
1 March 2016 | By Quotient Clinical
Quotient Clinical will be showcasing its Enabled-First-in-Human® programs at the upcoming ASCPT Meeting 2016...
ProStrakan reaches deal for Moventig with AstraZeneca
1 March 2016 | By Victoria White
ProStrakan will make an upfront payment to AstraZeneca of $70 million to acquire the rights to Moventig in the EU, Iceland, Norway, Switzerland and Liechtenstein...
CHMP adopts positive opinion of afatinib in SqCC
29 February 2016 | By Victoria White
The CHMP positive opinion is based on the results of the head-to-head LUX-Lung 8 trial in patients with SqCC...
New modern and specialized R&D and Test Center
29 February 2016 | By F.P.S. Food and Pharma Systems Srl
FPS is pleased to announce the opening of his new R&D and Test Center...
Celgene’s Imnovid and Abraxane recommended for use in Ireland
29 February 2016 | By Victoria White
Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane...
Tremelimumab mesothelioma trial fails to meet primary endpoint
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
Future proofing – Part 1. Modularity and flexibility – New LAB.line tablet hardness testers
29 February 2016 | By Arwid Ischi, Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain...
Boehringer Ingelheim launches two initiatives to help those living with IPF
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
